Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B E Strober

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
The British Journal of Dermatology|March 20, 2004
Toxic epidermal necrolysis-like reaction secondary to colchicine overdoseM P Arroyo, S Sanders, H Yee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 16, 2014
Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapyB E Strober, Y Poulin, C Teller, et al.
The British Journal of Dermatology|January 4, 2007
Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasisB Elewski, C Leonardi, A B Gottlieb, et al.
The British Journal of Dermatology|June 27, 2015
Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exerciseB E Strober, C E M Griffiths, S J O'Dell, et al.
The British Journal of Dermatology|October 10, 2017
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasisB E Strober, R G B Langley, A Menter, et al.
The British Journal of Dermatology|August 18, 2012
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trialB E Strober, J M Sobell, K C Duffin, et al.
Cell|October 7, 1994
The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrestJ L Dunaief, B E Strober, S Guha, et al.
The British Journal of Dermatology|April 27, 2012
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisA B Gottlieb, R G Langley, B E Strober, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 22, 2019
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis RegistryP J Mease, J B Palmer, P Hur, et al.
The British Journal of Dermatology|November 10, 2019
Defining drug-free remission of skin disease in patients with plaque psoriasisA W Armstrong, A Blauvelt, J J Crowley, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
The British Journal of Dermatology|March 20, 2004
Toxic epidermal necrolysis-like reaction secondary to colchicine overdoseM P Arroyo, S Sanders, H Yee, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 16, 2014
Changes in C-reactive protein in patients with moderate-to-severe psoriasis switched to adalimumab therapy after suboptimal response to etanercept, methotrexate or phototherapyB E Strober, Y Poulin, C Teller, et al.
The British Journal of Dermatology|January 4, 2007
Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasisB Elewski, C Leonardi, A B Gottlieb, et al.
The British Journal of Dermatology|June 27, 2015
Prioritizing the global research agenda in psoriasis: an International Psoriasis Council Delphi consensus exerciseB E Strober, C E M Griffiths, S J O'Dell, et al.
The British Journal of Dermatology|October 10, 2017
No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate-to-severe plaque psoriasisB E Strober, R G B Langley, A Menter, et al.
The British Journal of Dermatology|August 18, 2012
Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trialB E Strober, J M Sobell, K C Duffin, et al.
Cell|October 7, 1994
The retinoblastoma protein and BRG1 form a complex and cooperate to induce cell cycle arrestJ L Dunaief, B E Strober, S Guha, et al.
The British Journal of Dermatology|April 27, 2012
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisA B Gottlieb, R G Langley, B E Strober, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|January 22, 2019
Utilization of the validated Psoriasis Epidemiology Screening Tool to identify signs and symptoms of psoriatic arthritis among those with psoriasis: a cross-sectional analysis from the US-based Corrona Psoriasis RegistryP J Mease, J B Palmer, P Hur, et al.
The British Journal of Dermatology|November 10, 2019
Defining drug-free remission of skin disease in patients with plaque psoriasisA W Armstrong, A Blauvelt, J J Crowley, et al.
Pageof 3